How to Fight Insurance Denials for Rare Disease Therapies: Pompe, Fabry, Gaucher, MPS & More

If you or your child has been diagnosed with a rare disease—Pompe, Fabry, Gaucher, mucopolysaccharidosis (MPS), Batten CLN2, Niemann-Pick type C, phenylketonuria (PKU), or another lysosomal storage disorder—your physician has likely prescribed an enzyme replacement therapy (ERT), substrate reduction therapy (SRT), or gene therapy. These treatments are FDA-approved, lifesaving, and often the only available option. Yet insurers routinely deny them, citing cost (often $100,000 to $3 million annually per patient), labeling them "experimental," demanding step therapy for newly approved drugs, or questioning medical necessity for milder phenotypes. This guide walks you through the most common denial templates, the specific citations and registries insurers respect, and concrete steps to build a winning appeal.

---

Why Insurers Deny Rare Disease Therapies

Despite FDA orphan drug approvals under the Orphan Drug Act of 1983 and FDA breakthrough therapy designations, rare disease therapies face predictable denial patterns:

1. "Experimental or investigational"

Insurers claim the therapy lacks "proven efficacy" or is not "standard of care." This is particularly common for newly approved drugs (e.g., Nexviazyme for Pompe approved 2021, Elfabrio for Fabry approved 2023, Aqneursa for Niemann-Pick C approved September 2024) or for off-label use of drugs like Zavesca (miglustat) in NPC.

2. "Not medically necessary" or "does not meet severity criteria"

For late-onset or attenuated forms of disease (e.g., late-onset Pompe disease with preserved ambulation, Gaucher type 1 without bone crises, Fabry with single-organ involvement), insurers argue the patient is "too healthy" to justify the expense. They ignore the progressive, irreversible nature of these diseases.

3. Step therapy or "try a cheaper drug first"

For diseases with multiple approved therapies (e.g., Lumizyme vs. Nexviazyme for Pompe; Cerezyme vs. VPRIV vs. Cerdelga for Gaucher; Fabrazyme vs. Elfabrio for Fabry), insurers demand step therapy despite differences in mechanism, antibody cross-reactivity, route of administration, or patient-specific factors (e.g., CYP2D6 metabolizer status for Cerdelga, amenable mutations for Galafold).

4. "Requires prior authorization" or "policy exclusion"

Some plans exclude coverage for drugs administered via unusual routes (e.g., intracerebroventricular Brineura for Batten CLN2) or label orphan drugs as "specialty pharmacy only" then claim the specialty pharmacy contract doesn't cover the drug.

5. "Diagnosis not confirmed" or "lacks genetic testing"

Insurers may deny if only enzyme assay is provided without molecular genetic confirmation, or if the gene variant is not explicitly listed in FDA labeling (particularly for Galafold/migalastat, which requires an amenable GLA mutation).

---

The Citations Insurers Respect

Rare disease appeals succeed when you anchor arguments in FDA approval documents, disease-specific registries, consensus guidelines, and pivotal trials. Here are the authoritative sources by disease:

Pompe Disease (Acid Alpha-Glucosidase Deficiency)

• FDA approvals: Lumizyme (alglucosidase alfa) 2010 (infantile and late-onset), Nexviazyme (avalglucosidase alfa) August 2021 (all forms)
• ACMG Newborn Screening: Pompe added to Recommended Uniform Screening Panel (RUSP) 2015
• AANEM/AAN Pompe Consensus 2020 (Tarnopolsky et al.) — diagnostic and treatment algorithm emphasizing early ERT initiation
• Pompe Registry (Sanofi NCT00231400) — international natural history and treatment outcomes
• Pivotal trials: COMET (Nexviazyme NEJM 2021), Kishnani NEJM 2007 (infantile Pompe), van der Ploeg Lancet 2010 (late-onset)

Fabry Disease (Alpha-Galactosidase A Deficiency)

• FDA approvals: Fabrazyme (agalsidase beta) 2003; Elfabrio (pegunigalsidase alfa) May 2023; Galafold (migalastat) August 2018 (amenable mutations only)
• Ortiz 2018 Mol Genet Metab — International Working Group consensus on Fabry treatment initiation and monitoring
• Fabry Registry (NCT00196742) and HEED Fabry registry — natural history, cardiac/renal outcomes
• Galafold amenability list: FDA label includes specific GLA mutations responsive to chaperone therapy; non-amenable mutations require ERT
• Pivotal trials: BRIGHT (Elfabrio), ATTRACT/FACETS (Galafold)

Gaucher Disease (Glucocerebrosidase Deficiency)

• FDA approvals: Cerezyme (imiglucerase) 1994, VPRIV (velaglucerase alfa) 2010, Cerdelga (eliglustat) August 2014, Zavesca (miglustat) 2003 (type 1 unable to receive ERT)
• International Collaborative Gaucher Group (ICGG) Registry — treatment goals (Charrow, Pastores consensus)
• CYP2D6 genotyping: Cerdelga eligibility requires extensive or intermediate metabolizer status; poor metabolizers must use ERT
• Treatment goals: hemoglobin normalization, platelet >100k, liver/spleen volume reduction, bone pain/crisis prevention

Mucopolysaccharidoses (MPS I, II, IVA, VI, VII)

• FDA approvals:

- MPS I: Aldurazyme (laronidase) 2003

- MPS II (Hunter): Elaprase (idursulfase) 2006

- MPS IVA (Morquio A): Vimizim (elosulfase alfa) 2014

- MPS VI: Naglazyme (galsulfase) 2005

- MPS VII: Mepsevii (vestronidase alfa) 2017

• ACMG Newborn Screening: MPS I added to RUSP 2016
• NORD Physician Guides for each MPS subtype — natural history, treatment algorithm
• MPS Registry (NCT01524549) — long-term outcomes, growth velocity, respiratory function, 6-minute walk test

Batten Disease CLN2 (Tripeptidyl Peptidase-1 Deficiency)

• FDA approval: Brineura (cerliponase alfa) intracerebroventricular ERT, April 2017
• Schulz NEJM 2018 — pivotal trial showing motor and language function stabilization vs. natural history decline
• Hamburg CLN2 Scale — validated clinical outcome measure; natural history shows ~2 points/year decline without treatment

Niemann-Pick Disease Type C (NPC)

• FDA approval: Aqneursa (levacetylleucine/arimoclomol) September 2024 — first approved NPC therapy
• IB1001-301 trial (published in press) — slowed NPC Clinical Severity Scale progression
• Zavesca (miglustat) off-label: European approval 2009, widely used in US off-label; Pineda 2018 systematic review

Phenylketonuria (PKU)

• FDA approvals: Kuvan (sapropterin) December 2007 (BH4-responsive PKU); Palynziq (pegvaliase) May 2018 (uncontrolled PKU)
• ACMG PKU Guidelines — Phe target <360 µmol/L to prevent cognitive decline
• BH4 loading test — documents sapropterin responsiveness; non-responders require Palynziq or diet alone

AADC Deficiency

• FDA approval: Upstaza (eladocagene exuparvovec) June 2022 — gene therapy for aromatic L-amino acid decarboxylase deficiency
• Pivotal trial: AADC Gene Therapy Consortium — motor milestone acquisition post-gene therapy

---

How to Argue Against Each Denial Reason

1. "Experimental or investigational"

Insurer's argument: The therapy is not FDA-approved or lacks sufficient evidence.

Your counter:

• Cite the exact FDA approval date and indication. Example: "Nexviazyme received FDA approval on August 6, 2021, for late-onset Pompe disease (LOPD) under BLA 761211. It is not experimental; it is the FDA-approved standard of care."
• Invoke the Orphan Drug Act of 1983: "This drug was approved under the Orphan Drug Act for a disease affecting fewer than 200,000 Americans. The Act's statutory purpose is to incentivize development of therapies for rare diseases. Labeling an FDA-approved orphan drug 'experimental' contradicts federal policy and the FDA's determination."
• Reference disease-specific guidelines. Example for Pompe: "The 2020 AANEM/AAN consensus (Tarnopolsky et al.) recommends ERT initiation for all patients with confirmed Pompe disease and symptoms, regardless of phenotype severity."
• For newly approved drugs, cite pivotal trial and FDA review. Example for Aqneursa (NPC, approved Sept 2024): "Aqneursa's approval was based on the IB1001-301 trial demonstrating slowed disease progression on the NPC Clinical Severity Scale. FDA's press release (Sept 2024) explicitly recognizes no prior approved therapies existed. Denial contradicts FDA's benefit-risk determination."
• For off-label use (e.g., Zavesca in NPC prior to Aqneursa approval): "Zavesca is the only treatment endorsed in published systematic reviews (Pineda 2018) and European consensus guidelines. In the absence of an approved alternative [if prior to 2024], off-label use is medically necessary to prevent irreversible neurological decline."

Action steps:

1. Obtain the FDA approval letter and label from Drugs@FDA (www.accessdata.fda.gov/scripts/cder/daf/).

2. Request your metabolic geneticist include a statement: "This drug is FDA-approved for [patient's diagnosis]. There is no experimental aspect to this prescription."

3. Cite the pivotal trial by name (e.g., COMET, BRIGHT, Schulz NEJM 2018).

4. If your insurer's medical policy lists the drug as "investigational," request the policy document and note its publication date. Policies written before FDA approval are outdated; demand an updated medical necessity review.

---

2. "Not medically necessary" or "does not meet severity criteria"

Insurer's argument: The patient's disease is not severe enough to warrant expensive therapy. Common for late-onset Pompe, Gaucher type 1 without bone crises, or Fabry with single-organ involvement.

Your counter:

• Emphasize irreversibility: "Lysosomal storage diseases are progressive and irreversible. Delaying ERT until [cardiac fibrosis, respiratory failure, skeletal dysplasia] is advanced means permanent organ damage. The standard of care, per [Ortiz 2018 Fabry consensus / ICGG Gaucher treatment goals / Pompe Registry data], is to initiate therapy before irreversible damage."
• Document objective organ involvement:

- Pompe: upright and supine forced vital capacity (FVC), 6-minute walk test (6MWT), CK level, respiratory muscle weakness on pulmonary function tests.

- Fabry: left ventricular mass index (LVMI) on echocardiogram, eGFR, urine albumin-to-creatinine ratio (ACR), acroparesthesias, GI symptoms, stroke/TIA history.

- Gaucher: hemoglobin, platelet count, liver and spleen volume by MRI, bone pain/AVN, Kehr score.

- MPS: growth velocity, joint range of motion, hepatosplenomegaly, cardiac valve disease, airway obstruction, 6MWT or Functional Independence Measure.

• Cite newborn screening mandates. Example for Pompe: "Pompe was added to the ACMG Recommended Uniform Screening Panel in 2015 because early treatment improves outcomes. Denying therapy to a patient with confirmed enzyme deficiency and symptoms contradicts the public health rationale for screening."
• Use registry data. Example for late-onset Pompe: "The Pompe Registry (NCT00231400) shows that patients with baseline FVC 40–80% predicted who receive ERT have significantly slower FVC decline and longer ventilator-free survival than untreated historical controls. Delaying therapy until ventilator dependence is both cruel and more expensive."

Action steps:

1. Provide complete diagnostic confirmation: enzyme assay and molecular genetic testing (GAA, GLA, GBA, IDUA, IDS, GALNS, ARSB, TPP1, NPC1/NPC2, PAH gene).

2. Provide baseline and serial objective measures (echo, PFTs, 6MWT, Hamburg scale, NPC severity scale).

3. Request a letter from your geneticist stating: "There is no safe 'watch and wait' threshold for [disease]. The consensus standard is to treat once diagnosis and symptoms are confirmed."

4. If your insurer's policy requires "severe" disease, ask for the definition of "severe." Most policies do not define it; argue that any symptomatic, confirmed lysosomal storage disease meets medical necessity.

---

3. Step therapy or "try a cheaper drug first"

Insurer's argument: You must fail Drug A before we cover Drug B, even if your physician prescribed B for clinical reasons.

Your counter:

• Cite patient-specific factors:

- Pompe, switching from Lumizyme to Nexviazyme: "My physician prescribed Nexviazyme based on the COMET trial (NEJM 2021) showing superior respiratory and motor outcomes vs. alglucosidase alfa. I have [high sustained antibody titers / suboptimal response to Lumizyme]. Forcing re-trial of Lumizyme delays access to a superior therapy and risks irreversible decline."

- Gaucher, Cerdelga vs. ERT: "I am a CYP2D6 extensive metabolizer (genotype [X]). Cerdelga is FDA-approved specifically for my genotype and offers oral administration, avoiding the infusion burden and infusion reactions of Cerezyme. ICGG Registry data support substrate reduction as equally effective for type 1 Gaucher in appropriate patients."

- Fabry, Galafold vs. ERT: "I have the GLA mutation [p.N215S], which is on the FDA-approved amenability list for Galafold (migalastat). Galafold is a chaperone that stabilizes my residual enzyme; it is not interchangeable with ERT. For amenable mutations, FACETS trial data show Galafold is equally effective and preferred per Ortiz 2018 consensus."

• Document prior therapy if applicable: "I previously received [Lumizyme] from [date] to [date]. Response was [FVC stable but 6MWT declined 15%; or high anti-drug antibody titer]. Switching to [Nexviazyme] is clinically indicated, not a 'new' request."
• Cite non-interchangeability: "These are not 'me-too' drugs. [Nexviazyme] is a different glycoform with enhanced uptake. [Elfabrio] is PEGylated with reduced immunogenicity. Step therapy assumes interchangeability that does not exist."

Action steps:

1. For Galafold (Fabry), confirm your GLA mutation is on the FDA amenability list (available in the Galafold prescribing information and at galfold.com).

2. For Cerdelga (Gaucher), provide CYP2D6 genotype test showing extensive or intermediate metabolizer status.

3. For Pompe or Fabry switches, provide antibody titer data and clinical response metrics (FVC, 6MWT, LVMI, eGFR) showing suboptimal response or immunogenicity.

4. Request your physician write: "Step therapy is clinically inappropriate because [patient-specific reason]. Delaying [prescribed drug] will result in irreversible disease progression."

---

4. "Diagnosis not confirmed" or "lacks genetic testing"

Insurer's argument: Enzyme assay alone is insufficient; we require molecular genetic testing (or vice versa). Or: your gene variant is not listed in the FDA label.

Your counter:

• Provide both enzyme and genetic testing: "Diagnosis of [Pompe disease] was confirmed by both GAA enzyme activity [X nmol/h/mg, reference range >10] and molecular testing showing compound heterozygous pathogenic variants [c.-32-13T>G / c.525delT]. This exceeds ACMG diagnostic criteria."
• For Galafold denials (Fabry): "My GLA mutation [p.N215S] is explicitly listed in Table 1 of the Galafold prescribing information as amenable. The FDA approval was predicated on in vitro HEK assay data for this specific variant. Denial contradicts the FDA label."
• For novel or rare variants: "The variant [X] is classified as pathogenic in ClinVar [accession number] and HGMD. It is a [nonsense / frameshift / missense affecting active site]. Functional studies [cite if available] confirm loss of enzyme activity. The absence of this variant from a specific list does not negate pathogenicity; ACMG variant interpretation standards (Richards 2015) support pathogenic classification."
• CRIM status for Pompe: "For infantile-onset Pompe, I am CRIM-positive [or CRIM-negative], which informs immunomodulation strategy per Kishnani consensus. This confirms both diagnosis and treatment plan."

Action steps:

1. Ensure your genetic test report includes ACMG/AMP variant classification (pathogenic, likely pathogenic).

2. For Fabry + Galafold, cross-reference your mutation with the FDA-approved amenability list and include that page of the label in your appeal.

3. For Pompe, include CRIM status determination (immunoblot or genetic prediction).

4. Request your geneticist include a summary: "Diagnosis confirmed by [enzyme] and [genetic testing], meeting all ACMG diagnostic criteria for [disease]."

---

5. "Prior authorization expired" or "policy exclusion"

Insurer's argument: Coverage lapsed, or the drug is excluded from your plan's formulary or specialty pharmacy network.

Your counter:

• Prior authorization: "Prior authorization for [drug] was approved [date] for [duration]. The disease is chronic and progressive. Interrupting therapy causes irreversible harm. I request immediate reinstatement and a standing prior authorization for the duration of medical necessity, per NORD recommendations for chronic rare diseases."
• Specialty pharmacy exclusion: "This drug is FDA-approved and medically necessary. If [plan's specialty pharmacy] does not stock it, the plan must arrange an exception or out-of-network coverage at in-network cost-sharing under [state surprise billing law / ACA essential health benefits / ERISA fiduciary duty]. I will not be penalized for the plan's network gaps."
• Formulary exclusion: "The FDA has approved this drug for a life-threatening rare disease. Excluding it from the formulary is discriminatory under the ACA and may violate state parity laws for essential health benefits. I request an immediate formulary exception."

Action steps:

1. Check your plan's Summary of Benefits and Coverage (SBC) or Evidence of Coverage (EOC) for language on "essential health benefits" or "rare disease coverage."

2. Contact your state insurance commissioner if the plan excludes all therapies for your rare disease.

3. Request a formulary exception in writing, with a letter from your physician stating there is no therapeutic alternative.

4. If your state has an Orphan Drug Act or rare disease law (e.g., Connecticut, Illinois), cite it.

---

What We Do

We generate evidence-based, physician-ready appeal letters for rare disease therapy denials in minutes. You provide your diagnosis, genetic testing, organ involvement summary, and denial details. Our system cross-references FDA approval dates, amenability lists, CYP2D6 status, disease registries (Pompe, Fabry, Gaucher, MPS), consensus guidelines (AANEM, Ortiz, ICGG, ACMG), pivotal trial results (COMET, BRIGHT, FACETS, Schulz NEJM 2018), and your insurer's specific medical policy. The output is a structured letter citing the exact guidelines, trial data, and policy language that payers respect, ready for your metabolic geneticist or rare disease specialist to review, sign, and submit. Every citation is real; every argument is tailored to your case.

---

Sources

1. Orphan Drug Act of 1983, Pub. L. 97-414. US FDA Office of Orphan Products Development.

2. American College of Medical Genetics (ACMG) Newborn Screening ACT Sheets and Algorithms. Pompe added to RUSP 2015; MPS I added 2016. https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/ACT_Sheets_and_Algorithms.aspx

3. Tarnopolsky MA et al. AANEM/AAN consensus on Pompe disease diagnosis and management. Muscle Nerve 2020; 61(1): 4–20.

4. Pompe Registry (Sanofi Genzyme NCT00231400). International natural history and treatment outcomes registry.

5. Kishnani PS et al. Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007; 68(2): 99–109.

6. van der Ploeg AT et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010; 362(15): 1396–1406.

7. Diaz GA et al. (COMET trial) Avalglucosidase alfa vs. alglucosidase alfa in late-onset Pompe disease. N Engl J Med 2021; 385(26): 2418–2426.

8. Ortiz A et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 2018; 123(4): 416–427.

9. Fabry Registry (Genzyme NCT00196742) and HEED Fabry Outcomes Registry.

10. Galafold (migalastat) prescribing information, Amicus Therapeutics, updated 2023. Table 1: Amenable GLA mutations.

11. Charrow J, Pastores GM et al. International Collaborative Gaucher Group (ICGG) treatment goals and registry data. Am J Hematol 2004, 2011 updates.

12. Cerdelga (eliglustat) prescribing information, Genzyme, 2014. CYP2D6 genotype requirements.

13. Schulz A et al. Study of intracerebroventricular cerliponase alfa for CLN2 disease. N Engl J Med 2018; 378(20): 1898–1907.

14. Aqneursa (arimoclomol) prescribing information, Zevra Therapeutics, September 2024. FDA approval for NPC1. IB1001-301 trial.

15. Pineda M et al. Miglustat in patients with Niemann-Pick disease type C: a review. Orphanet J Rare Dis 2018; 13(1): 140.

16. National Organization for Rare Disorders (NORD) Physician Guides for MPS I, II, IVA, VI, VII; Pompe; Fabry; Gaucher; Batten CLN2; NPC; PKU. https://rarediseases.org/for-clinicians-and-researchers/

17. MPS Registry (Shire/Takeda NCT01524549).

18. Richards S et al. Standards and guidelines for the interpretation of sequence variants (ACMG/AMP). Genet Med 2015; 17(5): 405–424.

19. FDA Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/ — for approval letters, labels, and review documents.

20. American Academy of Neurology (AAN), American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), and disease-specific working groups—consensus statements for Pompe, MPS, and other rare diseases.

---

Disclaimer: This guide is for educational purposes. It does not constitute medical or legal advice. Always work with your treating physician and consider consulting a patient advocate or attorney experienced in insurance appeals for rare diseases.